00:04 , Jul 19, 2019 |  BC Extra  |  Financial News

Genmab’s plans after $500M NASDAQ debut

European bellwether Genmab plans to use a large chunk of the $505.9 million it raised through its listing on NASDAQ Thursday to fuel clinical development and commercialization of antibody-drug conjugate tisotumab vedotin (HuMax-TF-ADC). Two other...
21:21 , Jun 14, 2019 |  BioCentury  |  Product Development

Despite senior management shake-up, Novartis’ pipeline is primed to deliver

A string of departures at Novartis AG and strategic shifts by new CEO Vasant Narasimhan have produced a fairly thorough makeover of the executive committee he inherited in 2018. The team gains a pipeline that...
21:34 , May 28, 2019 |  BC Extra  |  Financial News

May 28 Financial Quick Takes: Alphamab Oncology raises $60M; plus $180.5M for Panacea healthcare fund and more

Hudson Bay leads Alphamab Oncology's $60M series B Alphamab Oncology (Cayman) raised $60 million in a series B round led by Hudson Bay Capital, with participation from new investor and entrepreneur Adrian Cheng and existing...
02:49 , Jan 5, 2019 |  BioCentury  |  Finance

Ready to launch

  The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record...
04:21 , Nov 30, 2018 |  BC Innovations  |  Targets & Mechanisms

Adhesion targets emerge at ASH 2018

The next wave of targets in blood cancers and hematology will come from adhesion molecules, innate immune cells and regulators of gene expression, according to BioCentury’s analysis of emerging targets at ASH 2018. BioCentury’s analysis...
17:02 , May 25, 2018 |  BC Week In Review  |  Clinical News

Genmab's Arzerra misses in Phase III for indolent NHL

Genmab A/S (CSE:GEN) said Arzerra ofatumumab plus Treanda bendamustine missed the primary endpoint of improving progression-free survival (PFS) in the Phase III COMPLEMENT A+B trial to treat indolent B cell non-Hodgkin's lymphoma (NHL). The company...
18:32 , May 24, 2018 |  BC Extra  |  Clinical News

Genmab's Arzerra misses in Phase III for indolent NHL

Genmab A/S (CSE:GEN) said Arzerra ofatumumab plus Treanda bendamustine missed the primary endpoint of improving progression-free survival (PFS) in the Phase III COMPLEMENT A+B trial to treat indolent B cell non-Hodgkin's lymphoma. The company said...
13:50 , Apr 13, 2018 |  BC Week In Review  |  Clinical News

FDA Priority Review for Verastem's duvelisib

Verastem Inc. (NASDAQ:VSTM) said FDA accepted and granted Priority Review to an NDA seeking full approval of duvelisib (IPI-145) to treat relapsed or refractory chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). The NDA...
20:33 , Apr 9, 2018 |  BC Extra  |  Company News

Verastem gains on duvelisib Priority Review

Verastem Inc. (NASDAQ:VSTM) added $0.32 (11%) to $3.22 on Monday after it said FDA accepted and granted Priority Review to an NDA seeking full approval of duvelisib (IPI-145) to treat relapsed or refractory chronic lymphocytic...
16:14 , Feb 9, 2018 |  BC Week In Review  |  Clinical News

Verastem submits NDA to FDA for duvelisib

Verastem Inc. (NASDAQ:VSTM) submitted an NDA to FDA for duvelisib (IPI-145) to treat relapsed or refractory chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). The NDA is also seeking accelerated approval of duvelisib to...